Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Non-Current Debt: 2022-2025

Historic Non-Current Debt for Taysha Gene Therapies (TSHA) over the last 4 years, with Sep 2025 value amounting to $50.9 million.

  • Taysha Gene Therapies' Non-Current Debt rose 18.34% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $50.9 million, marking a year-over-year increase of 18.34%. This contributed to the annual value of $43.9 million for FY2024, which is 8.48% up from last year.
  • Per Taysha Gene Therapies' latest filing, its Non-Current Debt stood at $50.9 million for Q3 2025, which was up 23.88% from $41.1 million recorded in Q2 2025.
  • Taysha Gene Therapies' 5-year Non-Current Debt high stood at $50.9 million for Q3 2025, and its period low was $37.4 million during Q1 2022.
  • Moreover, its 3-year median value for Non-Current Debt was $40.5 million (2024), whereas its average is $41.4 million.
  • As far as peak fluctuations go, Taysha Gene Therapies' Non-Current Debt fell by 1.35% in 2024, and later climbed by 18.34% in 2025.
  • Taysha Gene Therapies' Non-Current Debt (Quarterly) stood at $38.0 million in 2022, then climbed by 6.69% to $40.5 million in 2023, then grew by 8.48% to $43.9 million in 2024, then grew by 18.34% to $50.9 million in 2025.
  • Its last three reported values are $50.9 million in Q3 2025, $41.1 million for Q2 2025, and $42.5 million during Q1 2025.